Journal Image
Current Pharmaceutical Biotechnology
ISSN (Print): 1389-2010
ISSN (Online): 1873-4316
DOI: 10.2174/138920110792246465      Price:  $58

Molecular Probes for Malignant Melanoma Imaging

Author(s): Gang Ren, Ying Pan and Zhen Cheng
Pages 590-602 (13)
Malignant melanoma represents a serious public health problem and is a deadly disease when it is diagnosed at late stage. Though 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) has been widely used clinically for melanoma imaging, other approaches to specifically identify, characterize, monitor and guide therapeutics for malignant melanoma are still needed. Consequently, many probes targeting general molecular events including metabolism, angiogenesis, hypoxia and apoptosis in melanoma have been successfully developed. Furthermore, probes targeting melanoma associated targets such as melanocortin receptor 1 (MC1R), melanin, etc. have undergone active investigation and have demonstrated high melanoma specificity. In this review, these molecular probes targeting diverse melanoma biomarkers have been summarized. Some of them may eventually contribute to the improvement of personalized management of malignant melanoma.
Molecular Imaging, Melanoma, PET, Molecular Probe, MC1R, Melanin
Department of Radiology, Bio-X Program, Stanford Cancer Center, Canary Center at Stanford for Early Cancer Detection, 1201 Welch Road, Lucas Expansion, P020A, Stanford University, Stanford, CA 94305, USA.